Menu
Search
|

Menu

Close
X

Tetraphase Pharmaceuticals Inc TTPH.OQ (NASDAQ Stock Exchange Global Select Market)

3.11 USD
-0.23 (-6.89%)
As of 1:30 AM IST
chart
Previous Close 3.34
Open 3.35
Volume 260,279
3m Avg Volume 193,093
Today’s High 3.39
Today’s Low 3.07
52 Week High 8.75
52 Week Low 2.06
Shares Outstanding (mil) 51.05
Market Capitalization (mil) 396.17
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
2
FY17
10
FY16
5
FY15
12
EPS (USD)
FY18
-0.418
FY17
-2.715
FY16
-2.110
FY15
-2.370
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
79.06
5.73
Price to Book (MRQ)
vs sector
2.90
5.45
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.72
LT Debt to Equity (MRQ)
vs sector
0.00
12.39
Return on Investment (TTM)
vs sector
-73.69
14.61
Return on Equity (TTM)
vs sector
-73.76
16.34

EXECUTIVE LEADERSHIP

Leonard Patrick Gage
Chairman of the Board of Directors, Since 2011
Salary: --
Bonus: --
Guy Macdonald
President and Chief Executive Officer, Director, Since 2008
Salary: $420,000.00
Bonus: --
Larry Edwards
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Maria Stahl
Senior Vice President, General Counsel, Since 2015
Salary: --
Bonus: --
Larry Tsai
Chief Medical Officer, Since 2018
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

480 Arsenal St Ste 110
WATERTOWN   MA   02472-2891

Phone: +1617.7153600

Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections. The Company also develops TP-6076 for multidrug-resistant gram-negative infections. Eravacycline is a fluorocycline antibiotic. The Company is conducting a global Phase III clinical program for eravacycline called Investigating Gram-Negative Infections Treated with Eravacycline (IGNITE). TP-271 is a fully synthetic fluorocycline being developed for respiratory disease caused by bacterial biothreat pathogens in healthy volunteers.

SPONSORED STORIES